The role of resveratrol in diabetes and obesity associated with insulin resistance

References

• Arner, E., et al., 2010. Adipocyte turnover: relevance to human adipose tissue morphology. Diabetes, 59 (1), 105–109.
   PubMed Web of Science ®Google Scholar
• Baur, J.A., 2010. Biochemical effects of SIRT1 activators. Biochimica et biophysica acta, 1804 (8), 1626–1634.
   PubMed Web of Science ®Google Scholar
• Bhatt, J.K., Thomas, S., and Nanjan, M.J., 2012. Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus. Nutrition research, 32 (7), 537–541.
   PubMed Web of Science ®Google Scholar
• Bo, S., et al., 2016. Six months of resveratrol supplementation has no measurable effect in type 2 diabetic patients. A randomized, double blind, placebo-controlled trial. Pharmacological research, 111, 896–905.
   PubMed Web of Science ®Google Scholar
• Bordone, L., et al., 2006. Sirt1 regulates insulin secretion by repressing UCP2 in pancreatic β cells. PLoS biology, 4 (2), 210–220.
   Web of Science ®Google Scholar
• Brasnyó, P., et al., 2011. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. The British journal of nutrition, 106 (3), 383–389.
   PubMed Web of Science ®Google Scholar
• Chachay, V.S., et al., 2014. Resveratrol does not benefit patients with nonalcoholic fatty liver disease. Clinical gastroenterology and hepatology : The official clinical practice journal of the American gastroenterological association, 12 (12), 2092–2103.
   PubMed Web of Science ®Google Scholar
• Chan, C.B., et al., 2004. Uncoupling protein 2 and islet function. Diabetes, 53:(Supplement 1), S136–S142.
   PubMedGoogle Scholar
• Chen, L.L., et al., 2011. Resveratrol attenuates high-fat diet-induced insulin resistance by influencing skeletal muscle lipid transport and subsarcolemmal mitochondrial β-oxidation. Metabolism, 60 (11), 1598–1609.
   PubMed Web of Science ®Google Scholar
• Chen, S., et al., 2012. Effects of resveratrol on the amelioration of insulin resistance in KKAy mice. Canadian journal of physiology and pharmacology, 90 (2), 237–242.
   PubMed Web of Science ®Google Scholar
• Chi, T.C., et al., 2007. Phosphatidylinositol-3-kinase is involved in the antihyperglycemic effect induced by resveratrol in streptozotocin-induced diabetic rats. Life sciences, 80 (18), 1713–1720.
   PubMed Web of Science ®Google Scholar
• Colica, C., et al., 2018. A systematic review on natural antioxidant properties of resveratrol. Natural product communications, 13 (9), 1195–1203.
   Web of Science ®Google Scholar
• Dasgupta, B. and Milbrandt, J., 2007. Resveratrol stimulates AMP kinase activity in neurons. Proceedings of the national academy of sciences of the United States of America, 104 (17), 7217–7222.
   PubMed Web of Science ®Google Scholar
• Dash, S., et al., 2013. High-dose resveratrol treatment for 2 weeks inhibits intestinal and hepatic lipoprotein production in overweight/obese men. Arteriosclerosis, thrombosis, and vascular biology, 33 (12), 2895–2901.
   PubMed Web of Science ®Google Scholar
• Deng, J.Y., et al., 2008. Activation of estrogen receptor is crucial for resveratrol-stimulating muscular glucose uptake via both insulin-dependent and -independent pathways. Diabetes, 57 (7), 1814–1823.
   PubMed Web of Science ®Google Scholar
• Ding, S., et al., 2018. Resveratrol reduces the inflammatory response in adipose tissue and improves adipose insulin signalling in high-fat diet-fed mice. PeerJ, 6, 1–18.
   Web of Science ®Google Scholar
• Do, G.M., et al., 2012. Resveratrol ameliorates diabetes-related metabolic changes via activation of AMP-activated protein kinase and its downstream targets in db/db mice. Molecular nutrition & food research, 56 (8), 1282–1291.
   PubMed Web of Science ®Google Scholar
• EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). 2016. Safety of synthetic trans‐resveratrol as a novel food pursuant to regulation (EC) no 258/97. EFSA journal, 14 (1), 1–30.
   Web of Science ®Google Scholar
• Engin, A., 2017. Adiponectin-resistance in obesity. Obesity and lipotoxicity, 960, 415–441.
   Google Scholar
• Eseberri, I., et al., 2013. Resveratrol metabolites modify adipokine expression and secretion in 3T3-L1 pre-adipocytes and mature adipocytes. PLoS one, 8 (5), 1–8.
   Web of Science ®Google Scholar
• Fiori, J.L., et al., 2013. Resveratrol prevents β-cell dedifferentiation in nonhuman primates given a high-fat/high-sugar diet. Diabetes, 62 (10), 3500–3513.
   PubMed Web of Science ®Google Scholar
• Franco, J.G., et al., 2014. Resveratrol prevents hyperleptinemia and central leptin resistance in adult rats programmed by early weaning. Hormone and metabolic research = Hormon- Und Stoffwechselforschung = Hormones et Metabolisme, 46 (10), 728–735.
   PubMed Web of Science ®Google Scholar
• Ghadiri Soufi, F., et al., 2012. Long-term treatment with resveratrol attenuates oxidative stress pro-inflammatory mediators and apoptosis in streptozotocin-nicotinamide-induced diabetic rats. General physiology and biophysics, 31 (4), 431–438.
   PubMed Web of Science ®Google Scholar
• Goh, K.P., et al., 2014. Effects of resveratrol in patients with type 2 diabetes mellitus on skeletal muscle SIRT1 expression and energy expenditure. International journal of sport nutrition and exercise metabolism, 24 (1), 2–13.
   PubMed Web of Science ®Google Scholar
• Guo, R., et al., 2014. Resveratrol ameliorates diabetic vascular inflammation and macrophage infiltration in db/db mice by inhibiting the NF-κB pathway. Diabetes and vascular disease research, 11 (2), 92–102.
   PubMed Web of Science ®Google Scholar
• Hirsch, G.E. and Heck, T.G., 2019. Inflammation, oxidative stress and altered heat shock response in type 2 diabetes: the basis for new pharmacological and non-pharmacological interventions. Archives of physiology and biochemistry, 1–15.
   PubMed Web of Science ®Google Scholar
• Hoca, M., et al., 2020. The effect of resveratrol and quercetin on epithelial-mesenchymal transition in pancreatic cancer stem cell. Nutrition and cancer, 72 (7), 1231–1242.
   PubMed Web of Science ®Google Scholar
• Hou, X., et al., 2008. SIRT1 regulates hepatocyte lipid metabolism through activating AMP-activated protein kinase. The journal of biological chemistry, 283 (29), 20015–20026.
   PubMed Web of Science ®Google Scholar
• Huang, D.D., et al., 2020. A review on the potential of resveratrol in prevention and therapy of diabetes and diabetic complications. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 125, 1–15.
   Web of Science ®Google Scholar
• Huang, X. and Yang, Z., 2016. Resistin's, obesity and insulin resistance: the continuing disconnect between rodents and humans. Journal of endocrinological investigation, 39 (6), 607–615.
   PubMed Web of Science ®Google Scholar
• International Diabetes Federation. 2019. IDF Diabetes Atlas. 9th ed. Brussels, Belgium: International Diabetes Federation.
   Google Scholar
• Jimoh, A., et al., 2018. Resveratrol increases serum adiponectin level and decreases leptin and insulin level in an experimental model of hypercholesterolemia. Pathophysiology, 25 (4), 411–417.
   PubMedGoogle Scholar
• Kim, W.K., et al., 2019. The latest insights into adipokines in diabetes. Journal of clinical medicine, 8 (11), 1–6.
   Web of Science ®Google Scholar
• Kim, Y. and Park, C.W., 2016. Adenosine monophosphate-activated protein kinase in diabetic nephropathy. Kidney research and clinical practice, 35 (2), 69–77.
   PubMed Web of Science ®Google Scholar
• Koushki, M., et al., 2018. Resveratrol: a miraculous natural compound for diseases treatment. Food science & nutrition, 6 (8), 2473–2490.
   PubMed Web of Science ®Google Scholar
• Ku, C.R., et al., 2012. Resveratrol prevents streptozotocin-induced diabetes by inhibiting the apoptosis of pancreatic β-cell and the cleavage of poly (ADP-ribose) polymerase. Endocrine journal, 59 (2), 103–109.
   PubMed Web of Science ®Google Scholar
• Kumar, D.S., Shankar, P., and Rao, G.U., 2009. Health benefits of resveratrol. International journal of pharmaceutical sciences and nanotechnology, 2 (1), 407–412.
   Google Scholar
• Kuwabara, W.M.T., et al., 2017. Comparison of Goto-Kakizaki rats and high fat diet-induced obese rats: are they reliable models to study type 2 diabetes mellitus? PLoS One, 12 (12), 1–27.
   Web of Science ®Google Scholar
• Lan, F., et al., 2008. SIRT1 modulation of the acetylation status, cytosolic localization, and activity of LKB1 possible role in AMP-activated protein kinase activation. The journal of biological chemistry, 283 (41), 27628–27635.
   PubMed Web of Science ®Google Scholar
• Lee, S.M., et al., 2011. Prevention and treatment of diabetes with resveratrol in a non-obese mouse model of type 1 diabetes. Diabetologia, 54 (5), 1136–1146.
   PubMed Web of Science ®Google Scholar
• Lee, Y.E., et al., 2012. Chronic resveratrol treatment protects pancreatic islets against oxidative stress in db/db mice. PLoS One, 7 (11), 1–8.
   Web of Science ®Google Scholar
• Leitner, D.R., et al., 2017. Obesity and type 2 diabetes: two diseases with a need for combined treatment strategies – EASO can lead the way. Obesity facts, 10 (5), 483–492.
   PubMed Web of Science ®Google Scholar
• Lotfy, M., et al., 2017. Chronic complications of diabetes mellitus: a mini review. Current diabetes reviews, 13 (1), 3–10.
   PubMed Web of Science ®Google Scholar
• Morino, K., et al., 2012. Regulation of mitochondrial biogenesis by lipoprotein lipase in muscle of insulin-resistant offspring of parents with type 2 diabetes. Diabetes, 61 (4), 877–887.
   PubMed Web of Science ®Google Scholar
• Movahed, A., et al., 2013. Antihyperglycemic effects of short term resveratrol supplementation in type 2 diabetic patients. Evidence-based complementary and alternative medicine : eCAM, 2013, 1–11.
   Web of Science ®Google Scholar
• Neeland, I.J., et al., 2012. Dysfunctional adiposity and the risk of prediabetes and type 2 diabetes in obese adults. JAMA, 308 (11), 1150–1159.
   PubMed Web of Science ®Google Scholar
• Novelle, M.G., et al., 2015. Resveratrol supplementation: where are we now and where should we go? Ageing research reviews, 21, 1–15.
   PubMed Web of Science ®Google Scholar
• Olesen, J., et al., 2014. Exercise training, but not resveratrol, improves metabolic and inflammatory status in skeletal muscle of aged men. The journal of physiology, 592 (8), 1873–1886.
   PubMed Web of Science ®Google Scholar
• Oyenihi, O.R., et al., 2016. Antidiabetic effects of resveratrol: the way forward in its clinical utility. Journal of diabetes research, 2016, 1–14.
   Web of Science ®Google Scholar
• Palsamy, P. and Subramanian, S., 2009. Modulatory effects of resveratrol on attenuating the key enzymes activities of carbohydrate metabolism in streptozotocin–nicotinamide-induced diabetic rats. Chemico-biological interactions, 179 (2–3), 356–362.
   PubMed Web of Science ®Google Scholar
• Palsamy, P. and Subramanian, S., 2010. Ameliorative potential of resveratrol on proinflammatory cytokines, hyperglycemia mediated oxidative stress, and pancreatic beta-cell dysfunction in streptozotocin-nicotinamide-induced diabetic rats. Journal of cellular physiology, 224 (2), 423–432.
   PubMed Web of Science ®Google Scholar
• Pereira, S.S. and Alvarez-Leite, J.I., 2014. Adipokines: biological functions and metabolically healthy obese profile. Journal of receptor, ligand and channel research, 7, 15–25.
   Google Scholar
• Planas, J.M., Colom, H., and Juan, M.E., 2011. Resveratrol: a polyphenol with multiple effects. Recent advances in pharmaceutical sciences, 114, 101–120.
   Google Scholar
• Poulsen, M.M., et al., 2013. High-dose resveratrol supplementation in obese men: an investigator-initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition. Diabetes, 62 (4), 1186–1195.
   PubMed Web of Science ®Google Scholar
• Prakash, D. and Gupta, C., 2011. Role of phytoestrogens as nutraceuticals in human health. Pharmacologyonline, 1, 510–523.
   Google Scholar
• Repossi, G., Das, U.N., and Eynard, A.R., 2020. Molecular basis of the beneficial actions of resveratrol. Archives of medical research, 51 (2), 1–10.
   PubMed Web of Science ®Google Scholar
• Ruderman, N.B., et al., 2013. AMPK, insulin resistance, and the metabolic syndrome. The journal of clinical investigation, 123 (7), 2764–2772.
   PubMed Web of Science ®Google Scholar
• Saeedi, P., et al.,; IDF Diabetes Atlas Committee. 2019. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas. Diabetes research and clinical practice, 157, 1–10.
   Web of Science ®Google Scholar
• Schmidt, M.I. and Duncan, B.B., 2003. Diabesity: an inflammatory metabolic condition. Clinical chemistry and laboratory medicine, 41 (9), 1120–1130.
   PubMed Web of Science ®Google Scholar
• Shaito, A., et al., 2020. Potential adverse effects of resveratrol: a literature review. International journal of molecular sciences, 21 (6), 1–26.
   Web of Science ®Google Scholar
• Szkudelska, K., et al., 2019. Effects of resveratrol in Goto-Kakizaki rat, a model of type 2 diabetes. Nutrients, 11 (10), 1–18.
   Web of Science ®Google Scholar
• Szkudelska, K., Okulicz, M., and Szkudelski, T., 2020. Resveratrol reduces excessive cholesterol accumulation in Goto-Kakizaki rat, a model with congenital type 2 diabetes. Journal of physiology and pharmacology, 71 (4), 581–587.
   Web of Science ®Google Scholar
• Szkudelski, T. and Szkudelska, K., 2015. Resveratrol and diabetes: from animal to human studies. Biochimica et biophysica acta, 1852 (6), 1145–1154.
   PubMed Web of Science ®Google Scholar
• Tan, Z., et al., 2012. Caveolin-3 is involved in the protection of resveratrol against high-fat-diet-induced insulin resistance by promoting GLUT4 translocation to the plasma membrane in skeletal muscle of ovariectomized rats. The journal of nutritional biochemistry, 23 (12), 1716–1724.
   PubMed Web of Science ®Google Scholar
• Timmers, S., et al., 2011. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell metabolism, 14 (5), 612–622.
   PubMed Web of Science ®Google Scholar
• Um, J.H., et al., 2010. AMP-activated protein kinase-deficient mice are resistant to the metabolic effects of resveratrol. Diabetes, 59 (3), 554–563.
   PubMed Web of Science ®Google Scholar
• Wang, J., et al., 2019. Leptin promotes white adipocyte browning by inhibiting the Hh signaling pathway. Cells, 8 (4), 1–14.
   Web of Science ®Google Scholar
• Yang, Y., et al., 2016. Protective role of PPARdelta in lipoapoptosis of pancreatic β cells. Lipids, 51 (11), 1259–1268.
   PubMed Web of Science ®Google Scholar
• Yoshino, J., et al., 2012. Resveratrol supplementation does not improve metabolic function in nonobese women with normal glucose tolerance. Cell metabolism, 16 (5), 658–664.
   PubMed Web of Science ®Google Scholar
• Zarei, S., et al., 2016. Effect of resveratrol on resistin and apelin gene expressions in adipose tissue of diabetic rats. Turkish journal of medical sciences, 46 (5), 1561–1567.
   PubMed Web of Science ®Google Scholar
• Zhang, J., et al., 2012. The protective effect of resveratrol on islet insulin secretion and morphology in mice on a high-fat diet. Diabetes research and clinical practice, 97 (3), 474–482.
   PubMed Web of Science ®Google Scholar
• Zhang, X., et al., 2018. Unraveling the regulation of hepatic gluconeogenesis. Frontiers in endocrinology, 9, 1–17.
   PubMed Web of Science ®Google Scholar
• Zhou, L., et al., 2019. Deciphering the anti-obesity benefits of resveratrol: the ‘‘gut microbiota-adipose tissue’’ axis. Frontiers in endocrinology, 10, 1–14.
   PubMed Web of Science ®Google Scholar
• Zhu, W., et al., 2014. Effects and mechanisms of resveratrol on the amelioration of oxidative stress and hepatic steatosis in KKAy mice. Nutrition & metabolism, 11 (1), 1–11.
   PubMedGoogle Scholar